|
rdf:type |
|
|
lifeskim:mentions |
|
|
pubmed:issue |
7
|
|
pubmed:dateCreated |
2000-10-17
|
|
pubmed:abstractText |
The combination of paclitaxel with cisplatin or carboplatin has become the preferred chemotherapy regimen in the treatment of epithelial ovarian carcinoma. Anthracyclines also have activity in this disease. We conducted a Phase II study by using the combination of paclitaxel, cisplatin, and epirubicin for the treatment of advanced ovarian carcinoma.
|
|
pubmed:language |
eng
|
|
pubmed:journal |
|
|
pubmed:citationSubset |
AIM
|
|
pubmed:chemical |
|
|
pubmed:status |
MEDLINE
|
|
pubmed:month |
Oct
|
|
pubmed:issn |
0008-543X
|
|
pubmed:author |
|
|
pubmed:issnType |
Print
|
|
pubmed:day |
1
|
|
pubmed:volume |
89
|
|
pubmed:owner |
NLM
|
|
pubmed:authorsComplete |
Y
|
|
pubmed:pagination |
1547-54
|
|
pubmed:dateRevised |
2006-4-24
|
|
pubmed:meshHeading |
pubmed-meshheading:11013370-Adult,
pubmed-meshheading:11013370-Aged,
pubmed-meshheading:11013370-Antineoplastic Combined Chemotherapy Protocols,
pubmed-meshheading:11013370-Cisplatin,
pubmed-meshheading:11013370-Drug Administration Schedule,
pubmed-meshheading:11013370-Epirubicin,
pubmed-meshheading:11013370-Female,
pubmed-meshheading:11013370-Granulocyte Colony-Stimulating Factor,
pubmed-meshheading:11013370-Humans,
pubmed-meshheading:11013370-Infusions, Intravenous,
pubmed-meshheading:11013370-Middle Aged,
pubmed-meshheading:11013370-Ovarian Neoplasms,
pubmed-meshheading:11013370-Paclitaxel,
pubmed-meshheading:11013370-Treatment Outcome
|
|
pubmed:year |
2000
|
|
pubmed:articleTitle |
Paclitaxel, cisplatin, and epirubicin first-line chemotherapy in stage III and IV ovarian carcinoma: long-term results of a phase II study.
|
|
pubmed:affiliation |
Department of Clinical Therapeutics, Alexandra Hospital, Athens University School of Medicine, Athens, Greece. mdimop@cc.uoa.gr
|
|
pubmed:publicationType |
Journal Article,
Clinical Trial,
Clinical Trial, Phase II
|
